type here...

CATEGORIES

Discover Drugs

LATEST

123Page 1 of 3

TRENDING

EDITORS CHOICE

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life -
SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Is Silmitasertib the Covid-19 Treatment Breakthrough We’ve Been Waiting for?

Medika Life -
Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.

Alterity and UniQuest Partner to Reverse Bacterial Resistance to Antibiotics

Medika Life -
Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

Why We Should Be Cautious With COVID-19 Medical Research

Dr Jeff Livingston -
Thalidomide’s history is a grim reminder of what can go wrong when a drug comes to market without proper clinical trials and oversight.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories